Atlas of confounding factors in head and neck PET/CT imaging

Clinical Nuclear Medicine

Volumn 36, Issue 5, 2011, Pages

  Bhargava, Peeyush ^a   Rahman, Saiyyeda ^a   Wendt, Juliet ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

artifacts; FDG; head and neck; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ARTICLE; ASPIRATION BIOPSY; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; EPIGLOTTIS CANCER; FALSE POSITIVE RESULT; GLUCOSE BLOOD LEVEL; HEAD AND NECK CANCER; HEAD AND NECK TUMOR; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LARYNX CANCER; LUNG CANCER; LYMPHADENOPATHY; MALE; MASTICATORY MUSCLE; MEDICAL HISTORY; METASTASIS; PAROTID GLAND TUMOR; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; RECURRENT CANCER; RISK FACTOR; SIALOADENITIS; SQUAMOUS CELL CARCINOMA; STERNOCLEIDOMASTOID MUSCLE; T CELL LYMPHOMA; THYROID ADENOMA; TONSIL CANCER; VILLOUS ADENOMA; VOCAL CORD PARALYSIS; WARTHIN TUMOR;

ARTIFACTS; BIOLOGICAL TRANSPORT; FLUORODEOXYGLUCOSE F18; HEAD; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INFLAMMATION; MALE; NECK; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79955055293     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318212c872     Document Type: Article

References (45)

1. Poeppel TD, Krause BJ, Heusner TA, et al. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol. 2009;70:382-392.
2. Højgaard L, Specht L. PET/CT in head and neck cancer. Eur JNucl Med Mol Imaging. 2007;34:1329-1333. (Pubitemid 47312581)
3. Gordin A, Golz A, Keidar Z, et al. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care. Otolaryngol Head Neck Surg. 2007;137:130-137. (Pubitemid 46962148)
4. Schöder H, Fury M, Lee N, et al. PET monitoring of therapy response in head and neck squamous cell carcinoma. JNucl Med. 2009;50:74S-88S.
5. Lonneux M, Hamoir M, Reychler H, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol. 2010;28:1190-1195.
6. Rosenbaum SJ, Lind T, Antoch G, et al. False-positive FDG PET uptake-the role of PET/CT. Eur Radiol. 2006;16:1054-1065.
7. Goerres GW, von Schulthess GK, Steinert HC. Why most PET of lung and head-and-neck cancer will be PET/CT. J Nucl Med. 2004;45:66S-71S.
8. Blodgett TM, Fukui MB, Snyderman CH, et al. Combined PET-CT in the head and neck: part 1. Physiologic, altered physiologic, and artifactual FDG uptake. Radiographics. 2005;25:897-912. (Pubitemid 41196928)
9. Fukui MB, Blodgett TM, Snyderman CH, et al. Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics. 2005;25:913-930. (Pubitemid 41196929)
10. Kapoor V, Fukui MB, McCook BM. Role of 18FFDG PET/CT in the treatment of head and neck cancers: posttherapy evaluation and pitfalls. Am J Roentgenol. 2005;184:589-597. (Pubitemid 46657272)
11. Liu Y, Ghesani NV, Zuckier LS. Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. Semin Nucl Med. 2010; 40:294-315.
12. Jackson RS, Schlarman TC, Hubble WL, et al. Prevalence and patterns of physiologic muscle uptake detected with whole-body 18F-FDG PET. J Nucl Med Technol. 2006;34:29-33. (Pubitemid 46768410)
13. Bar-Shalom R. Muscle uptake of 18-fluorine fluorodeoxyglucose. Semin Nucl Med. 2000;30:306-309.
14. Hany TF, Gharehpapagh E, Kamel EM, et al. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region Eur J Nucl Med Mol Imaging. 2002;29:1393-1398. (Pubitemid 44392224)
15. Cohade C, Osman M, Pannu HK, et al. Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT. J Nucl Med. 2003;44:170-176.
16. Aukema TS, Vogel WV, Hoefnagel CA, et al. Prevention of brown adipose tissue activation in 18F-FDG PET/CT of breast cancer patients receiving neoadjuvant systemic therapy. J Nucl Med Technol. 2010;38:24-27.
17. Gelfand MJ, O'hara SM, Curtwright LA, et al. Pre-medication to block [(18)F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients. Pediatr Radiol. 2005;35:984-990. (Pubitemid 41403488)
18. Cohade C. Altered biodistribution on FDG-PET with emphasis on brown fat and insulin effect. Semin Nucl Med. 2010;40:283-293.
19. Heusner TA, Hahn S, Hamami ME, et al. Incidental head and neck (18)F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development? Eur J Nucl Med Mol Imaging. 2009;36: 1397-1406.
20. Nakamoto Y, Tatsumi M, Hammoud D, et al. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology. 2005;234:879-885. (Pubitemid 40250832)
21. Komissarova M, Wong KK, Piert M, et al. Spectrum of 18F-FDG PET/CT findings in oncology-related recurrent laryngeal nerve palsy. Am J Roentgenol. 2009;192:288-294.
22. Bhargava P, Zhuang H, Kumar R, et al. Iatrogenic artifacts on whole-body F-18 FDG PET imaging. Clin Nucl Med. 2004;29:429-439. (Pubitemid 38780612)
23. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography Circulation. 2002;105:2708-2711. (Pubitemid 34615139)
24. Tatsumi M, Cohade C, Nakamoto Y, et al. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology. 2003;229:831-837. (Pubitemid 37467590)
25. Van der Wall EE, Schuijf JD, Jukema JW, et al. Atherosclerotic plaque imaging by PET/CT; can inactive, active and mixed plaques be discerned? Int J Cardiovasc Imaging. 2009;25:141-144.
26. Wang CH, Sun SS, Hsieh TC, et al. Unexpected left-sided pulmonary aspiration misdiagnosed as malignancy in PET cancer screening following panendoscopy cancer screening under conscious sedation. Clin Nucl Med. 2010;35:604-606.
27. Lin WY, Tsai SC, Hung GU. FDG-PET findings in barium aspiration. Clin Nucl Med. 2005;30:331-332.
28. Chen SW, Yang SN, Liang JA, et al. The outcome and prognostic factors in patients with aspiration pneumonia during concurrent chemoradiotherapy for head and neck cancer. Eur J Cancer Care (Engl). 2010;19:631-635.
29. Basu S, Houseni M, Alavi A. Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management. Nucl Med Commun. 2008;29:367-373. (Pubitemid 351644386)
30. 18F-FDG PET/CT in the incidental findings of parotid masses. Ann Nucl Med. 2010;24:571-577.
31. Shie P, Cardarelli R, Sprawls K, et al. Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009;30:742-748.
32. Liu Y. Clinical significance of thyroid uptake on F18-fluorodeoxyglucose positron emission tomography. Ann Nucl Med. 2009;23:17-23.
33. Modi D, Fulham MJ, Mohamed A, et al. Intraluminal FDG uptake in a rectal polyp detected with PET CT: identification of an unsuspected synchronous primary bowel tumor. Clin Nucl Med. 2005;30:180-181. (Pubitemid 40270966)
34. Gutman F, Alberini JL, Wartski M, et al. Incidental colonic focal lesions detected by FDG PET/CT. Am J Roentgenol. 2005;185:495-500.
35. Kei PL, Vikram R, Yeung HW, et al. Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results. Am J Roentgenol. 2010;194:401-406.
36. Krabbe CA, Pruim J, van der Laan BF, et al. FDG-PET and detection of distant metastases and simultaneous tumors in head and neck squamous cell carcinoma: a comparison with chest radiography and chest CT. Oral Oncol. 2009;45:234-240.
37. Choi JY, Lee KS, Kwon OJ, et al. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol. 2005;23:7654-7659. (Pubitemid 46291830)
38. Strobel K, Haerle SK, Stoeckli SJ, et al. Head and neck squamous cell carcinoma (HNSCC)-detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:919-927.
39. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89:1019-1025.
40. Schöder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med. 2004;34:180-197. (Pubitemid 38887174)
41. Schmid DT, Stoeckli SJ, Bandhauer F, et al. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope. 2003;113: 888-891. (Pubitemid 36539165)
42. Ferlito A, Shaha AR, Silver CE, et al. Incidence and sites of distant metastases from head and neck cancer. J Otorhinolaryngol Relat Spec. 2001;63:202-207. (Pubitemid 32620169)
43. Shintani SA, Foote RL, Lowe VJ, et al. Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:322-329.
44. Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130:105-109. (Pubitemid 38095439)
45. Beyer T, Tellmann L, Nickel I, et al. On the use of positioning aids to reduce misregistration in the head and neck in whole-body PET/CT studies. J Nucl Med. 2005;46:596-602. (Pubitemid 41716403)